[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-372432-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-372432-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","toxicities-of-parp-inhibitors-in-genitourinary-cancers-purpose-of-review-summary-recent-findings","Toxicities of PARP inhibitors in genitourinary cancers - Purpose of review - Summary - Recent findings","","Review of recent advancements on the genetic background of genitourinary cancers highlights targeted antitumor strategies in prostate cancer. PARP inhibitors have become increasingly studied, including earlier disease stages, yet they carry clinically meaningful toxicity. Hematologic adverse events—especially anemia, thrombocytopenia, and neutropenia—require regular blood count monitoring. Nonhematologic effects such as fatigue, nausea, vomiting, diarrhea, and constipation are common and can be reduced with supportive care. Persistent cytopenia may signal myelodysplastic syndrome or acute myeloid leukemia and warrants further evaluation.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/toxicities-of-parp-inhibitors-in-genitourinary-cancers-purpose-of-review-summary-recent-findings/372432/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/toxicities-of-parp-inhibitors-in-genitourinary-cancers-purpose-of-review-summary-recent-findings/372432.png","ImageObject",300,407,{"name":42,"@type":43},"Quinn Holloway","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-27","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",12,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why are PARP inhibitors important in prostate cancer treatment?","Question",{"text":63,"@type":64},"PARP inhibitors have transformed the treatment landscape of metastatic prostate cancer and are increasingly studied in earlier disease stages, offering meaningful survival benefit in applicable cases.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What are the most common serious toxicities from PARP inhibitors?",{"text":68,"@type":64},"Hematologic toxicities are among the most common and serious events, particularly anemia, thrombocytopenia, and neutropenia, which make regular blood count monitoring essential.",{"name":70,"@type":61,"acceptedAnswer":71},"How can nonhematologic side effects of PARP inhibitors be managed?",{"text":72,"@type":64},"Fatigue, nausea, vomiting, diarrhea, and constipation are common and can often be mitigated with supportive interventions such as dietary modifications, antiemetics, and stool management techniques.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},372432,1790445688,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":108,"slug":109},7,40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},8,"Research & Report",30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":107,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":97,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145},2336474466712,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","REVIEW  \nUPRI RNIENTON Toxicities of PARP inhibitors in genitourinary cancers  \nJnos Szalontaia, Tibor Szarvasa,b, Marcin Miszczykc,d, Pter Nyirdya, Shahrokh F. Shariata,e,f,g,h,i,j and Tams Fazekasa,c,k  \nPurpose of review  \nRecent advancements in the understanding of the genetic background of genitourinary cancers allowed fora successful introduction of targeted antitumor agents to prostate cancer (PCa) treatment. Inhibitors of the poly ADP-ribose polymerase enzyme (PARPi) transformed the treatment landscape of metastatic prostate cancer, and being increasingly studied in earlier disease stages. However, they are associated with nonnegligible toxicity, therefore, we aimed to summarize their side-effect profile in patients with PCa.  \nRecent findings  \nHematologic toxicities, particularly anemia, thrombocytopenia, and neutropenia are among the most common and serious adverse events associated with PARPi, highlighting the need for regular blood count monitoring. Nonhematologic side effects, including fatigue, nausea, vomiting, diarrhea, and constipation, are common, and can be mitigated with supportive interventions like dietary modifications, antiemetics, or stool management techniques. Special attention should be given to patients with therapy-resistant or persistent cytopenia, in whom bone marrow biopsy should be considered, as it can indicate myelodysplastic syndrome and acute myeloid leukemia.  \nSummary  \nPARP inhibitors represent a major advancement in the management of metastatic prostate cancer, offering a significant survival benefit in applicable cases. However, patients need to be carefully selected and informed, to allow for optimal balancing between the benefits and nonneglectable risks of severe toxicities. Better understanding of PARPi toxicity profile can improve personalized decision-making and enhance treatment compliance, through raising patients’ awareness about the possible side effects of PARPi.  \nKeywords  \nadverse event, anemia, BRCA, fatigue, genetic test, niraparib, olaparib, poly ADP-ribose polymerase inhibitors, prostate cancer, side effects, talazoparib, toxicity  \nINTRODUCTION – THE UTILITY OF POLY ADP-RIBOSE POLYMERASE INHIBITORS IN UROLOGICAL MALIGNANCIES  \nOwing to the recommendations against systematic screening, the incidence of metastatic prostate cancer has been steadily increasing, placing a significant burden on healthcare systems [1,2] . While androgen deprivation therapy (ADT) remains the backbone of treatment for metastatic disease, several other agents and their combinations became standard of care, including androgen receptor pathway inhibitors (ARPI), taxane chemotherapy (docetaxel, cabazitaxel), radioligands, and poly ADP-ribose polymerase inhibitors (PARPi) such as rucaparib, olaparib, and talazoparib [3] . Consequently, with the expanding treatment landscape, the opportunity for personalized therapies has improved, including the use of PARPi [4&&] . The inhibition of base-excision repair enzymes PARP 1 and 2, induces tumor cell death, particularly in cells harboring deficiencies in  \naDepartment of Urology, Semmelweis University, Budapest, Hungary, bDepartment of Urology, University of Duisburg-Essen and German Cancer Consortium (DKTK)-University Hospital Essen, Essen, Germany, cDepartment of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria, dCollegium Medicum – Faculty of Medicine, WSB University, Dabrowa Górnicza, Poland, eDepartment  \n̨  \nof Urology, University of Texas Southwestern Medical Center, Dallas, Texas, USA, fDepartment of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic, gDepartment of Urology, Weill Cornell Medical College, New York, New York, USA, hKarl Landsteiner Institute of Urology and Andrology, Vienna, Austria, iResearch Centre for Evidence Medicine, Urology Department, Tabriz University of Medical Sciences, Tabriz, Iran, jHourani Center for Applied Scientific Research, Al-Ahliyya Amman Univer","cbCaio787WAtJ8Pv","https://ap.wps.com/l/cbCaio787WAtJ8Pv","pdf",828679,"English","# Purpose of review\n# Recent findings\n# Summary\n# Introduction: The utility of poly ADP-ribose polymerase inhibitors in urological malignancies\n# Key points","[{\"question\":\"Why are PARP inhibitors important in prostate cancer treatment?\",\"answer\":\"PARP inhibitors have transformed the treatment landscape of metastatic prostate cancer and are increasingly studied in earlier disease stages, offering meaningful survival benefit in applicable cases.\"},{\"question\":\"What are the most common serious toxicities from PARP inhibitors?\",\"answer\":\"Hematologic toxicities are among the most common and serious events, particularly anemia, thrombocytopenia, and neutropenia, which make regular blood count monitoring essential.\"},{\"question\":\"How can nonhematologic side effects of PARP inhibitors be managed?\",\"answer\":\"Fatigue, nausea, vomiting, diarrhea, and constipation are common and can often be mitigated with supportive interventions such as dietary modifications, antiemetics, and stool management techniques.\"}]","Toxicities of PARP inhibitors in genitourinary cancers - Purpose of review - Summary - Recent findings | PDF",1790194509,13]